Abstract:Objective\r\nTo evaluate the effect of oxycodone hydrochloride controlled-release tablets for titration in treating moderate to severe cancer pain in a prospective, multicenter, randomized, parallel, controlled study.\r\n\r\n\r\nMethods\r\nHospitalized cancer patients with moderate to severe pain, aged 18-64 yr, weighing 48-69 kg, with numerical rating scale(NRS)score ≥ 4 points, were divided into 4 groups according to the multicenter stratified block randomization: naive IR group, naive CR group, tolerant IR group, and tolerant CR group.A 72-h rapid titration protocol was adopted, the initial dosage: immediate-release morphine tablets 10 mg in naive IR group, oxycodone hydrochloride controlled-release tablets 10 mg in naive CR group, and 10% of the total equivalent dosage of immediate-release morphine tablets (total opioids dosage) used the day before oral administration in tolerant IR group, 10% of the total equivalent dosage of oxycodone hydrochloride controlled-release tablets (total opioids dosage)used the day before oral administration in tolerant CR group.Titration method: pain assessment was performed every hour after administration until patients went to bed; when the NRS score was increased and ≥7 points, the equivalent immediate-release morphine tablet dose was increased by 100% than the previous dose; when the NRS score was not increased but still ≥7 points, the equivalent immediate-release morphine tablet dose was increased by 50% than the previous dose; when the NRS score was 4-6 points, the equivalent immediate-release morphine tablet dose was the same as before; when the NRS score was decreased and ≤3 points, patients were continuously observed without additional medication.Maintenance method: after the end of titration, the total amount of immediate-release morphine tablets for titration was converted into an equivalent dose of oxycodone hydrochloride controlled-release tablets and was given once a day for 2 days in naive IR and tolerant IR groups; the initial dose of oxycodone hydrochloride controlled-release tablets plus the total amount of immediate-release morphine tablets for titration was converted into an equivalent dose of oxycodone hydrochloride controlled-release tablets and was given once a day for 2 days in naive CR group and tolerant CR group.When break-through pain occurred, immediate release morphine tablets 5-10 mg was taken orally to record administration, degree of pain relief, dose of oxycodone hydrochloride controlled-release tablets used, titration cycle and amount, and the effective analgesia and adverse reactions were recorded.\r\n\r\n\r\nResults\r\nCompared with naive IR group, the titration cycle and total titration dose were significantly reduced, the rate of effective analgesia was increased, the degree of pain relief was better, the frequency of oral morphine tablets was reduced, and the dosage of oxycodone hydrochloride controlled-release tablets used was decreased in naive CR group (P 0.05).\r\n\r\n\r\nConclusion\r\nOxycodone hydrochloride controlled-release tablets for titration provide better efficacy in treating moderate to severe cancer pain.\r\n\r\n\r\nKey words: \r\nOxycodone; Pain; Cancer

PHASE II CLINICAL STUDY OF THE ANALGESIC EFFICACY OF INSTANT RELEASED OXYCODONE HYDROCHLORIDE FOR CANCER PAIN

Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study.

Efficacy and Safety of Sustained-Release Oxycodone Compared with Immediate-Release Morphine for Pain Titration in Cancer Patients: A Multicenter, Open-Label, Randomized Controlled Trial (SOCIAL).

Clinical Study of Titration Treatment for Moderate Cancer Pain with Oxycodone Hydrochloride Sustained-release Tablets

Comparative study of controlled-release oxycodone combined with morphine tablets for 12 hours or 24 hours for the treatment of cancer pain

Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial

Clinical study of Controlled-Release Oxycodone on moderate and severe chronic cancer pain

Clinical observation of oxycodone hydrochloride controlled-release tablet for moderate to severe cancer pain

Multicenter Trial Of Titration Of Morphine Versus Oxycodone For Cancer Pain

Oxycodone Hydrochloride Controlled-Release Tablets (oxycontin®): Post-Marketing Surveillance (PMS) Study for Relieving Moderate to Severe Non-Cancer Pain

Efficacy of oxycodone hydrochloride controlled-release tablets for titration in treating moderate to severe cancer pain: a prospective, multicenter, randomized, parallel, controlled study

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

Clinical Observation of Oxycodone Hydrochloride Controlled-release Tablets in the Treatment of Moderate to Severe Cancer Pain

Efficacy and Safety of High-Dose Controlled-Released Oxycodone for Cancer Pain

Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain

Effect of hydrochloride oxycodone controlled-release tablets with dose titration for moderate or severe cancer pain

Health Informatics of Oxycodone Hydrochloride Sustained-Release Tablets for Cancer Pain Treatment with Support of Computed Tomography Diagnosis

Cancer Pain Treated with Rectally Administered Prolonged-Release Oxycodone Hydrochloride Tablets

The therapeutic efficacy of oxycodone hydrochloride prolonged-release tablets combined with bioelectric stimulation in treatment Of neuropathological cancer pain

Clinical effects of morphine sulfate sustained-release tabelets in the treatment of severe cancer pain

The observation of curative effect of oxycodone hydrochloride controlled-release tablets in management of moderate and severe cancer pain